Searchable abstracts of presentations at key conferences in endocrinology

ea0011oc19 | Clinical endocrinology | ECE2006

Disease remission in long term treated acromegalic patients after somatostatin analog withdrawal

Ronchi CL , Varca V , Lania A , Arosio M , Spada A , Beck-Peccoz P

Long acting somatostatin analogs (SSTa) induce both GH/IGF-I reduction and pituitary tumor volume shrinkage in the majority of acromegalic patients. It is not known if SSTa might also definitively cure the acromegalic disease in at least some patients. Aim of the present study was to evaluate this possibility in acromegalic patients very well responsive to chronic treatment. Thirteen acromegalic patients (4M&9F), 5 newly diagnosed and 8 previously operated but none irradia...

ea0011p193 | Clinical practise and governance | ECE2006

Adequacy of post-glucose gh nadir <1 μg/l to define biochemical and neuroradiological remission of acromegaly

Ronchi CL , Varca V , Giavoli C , Ferrante E , Lania A , Arosio M , Beck-Peccoz P , Spada A

We previously demonstrated that acromegalic patients with normal IGF-I levels after surgery also met the current criteria for cure (i.e. postglucose GH nadir <1 μg/l) after long term monitoring. Since some Authors recently proposed to even lower the present GH nadir cut off value, the aim of this study was to confirm its adequacy to define long lasting disease remission. A group of 24 acromegalic patients (9 M&15 F, age 54.2±9.6 yrs) normal IGF-I levels and p...